Evidence map›Paper›PMID 33637963›Full record

ArticleNature genetics2021

Author Correction: Genome-wide meta-analysis, fine-mapping and integrative prioritization implicate new Alzheimer's disease risk genes.

Jeremy Schwartzentruber, Sarah Cooper, Jimmy Z Liu, Inigo Barrio-Hernandez, Erica Bello, Natsuhiko Kumasaka, Adam M H Young, Robin J M Franklin, Toby Johnson, Karol Estrada and 3 more

Abstract readPublished Erratum
PubMed Publisher
In one paragraph

Article in Nature genetics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Jeremy SchwartzentruberEuropean Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Cambridge, UK. jeremys@ebi.ac.uk.ORCID http://orcid.org/0000-0002-6183-2092
Sarah CooperOpen Targets, Wellcome Genome Campus, Cambridge, UK.
Jimmy Z LiuBiogen, Cambridge, MA, USA.
Inigo Barrio-HernandezEuropean Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Cambridge, UK.ORCID http://orcid.org/0000-0002-5686-0451
Erica BelloOpen Targets, Wellcome Genome Campus, Cambridge, UK.
Natsuhiko KumasakaWellcome Sanger Institute, Wellcome Genome Campus, Cambridge, UK.ORCID http://orcid.org/0000-0002-3557-0375
Adam M H YoungWellcome-Medical Research Council Cambridge Stem Cell Institute, Cambridge Biomedical Campus, University of Cambridge, Cambridge, UK.
Robin J M FranklinWellcome-Medical Research Council Cambridge Stem Cell Institute, Cambridge Biomedical Campus, University of Cambridge, Cambridge, UK.
Toby JohnsonTarget Sciences-R&D, GSK Medicines Research Centre, Stevenage, UK.
Karol EstradaBioMarin Pharmaceutical, San Rafael, CA, USA.
Daniel J GaffneyOpen Targets, Wellcome Genome Campus, Cambridge, UK.ORCID http://orcid.org/0000-0002-1529-1862
Pedro BeltraoEuropean Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Cambridge, UK.ORCID http://orcid.org/0000-0002-2724-7703
Andrew BassettOpen Targets, Wellcome Genome Campus, Cambridge, UK. ab42@sanger.ac.uk.ORCID http://orcid.org/0000-0003-1632-9137

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID33637963

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.